Figure 4
From: Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer
Kaplan-Meier survival curves illustrating the significance of ezrin and p-ezrin expression in early-stage NSCLCs. In early-stage NSCLCs (stages I–II, n = 98), patients with high ezrin and ezrinThr567 levels had significantly reduced NSCLC-specific overall survival rates relative to those with low ezrin and ezrinThr567 levels (log-rank P = 0.030), respectively. However, ezrinTyr353 was not related with the survival of patients with early-stage NSCLC.